For the multiple medicinal herbs approach, our primary product is RM01, an extract from medicinal herbs, had been used in humans and has brought significant cognition improvements for severe, moderate, and mild Alzheimer patients. We utilized the mouse model, cell assays and in the combination of other methods, we found RM01 was able to reduce beta amyloid, reduce inflammation, and control the function of microglia. RenuMemo therapeutics is in the process of further understanding the mechanisms.
For the multiple chemical compounds’ strategy, we have selected small molecule compounds, which had been proved with functions that are connected with symptoms of Alzheimer’s disease. It optimized the ratio and concentration by our unique methodology to form RM02. The goal is to find the specificity and efficacy that are significantly higher than the individual compound used alone.
